H
Hana Pharm Co Ltd
KRX:293480
Hana Pharm Co Ltd
KRX:293480
Price:
9 310
KRW
-1.9%
Market Closed
Market Cap:
₩165.4B
Relative Value
The Relative Value of one Hana Pharm Co Ltd stock under the Base Case scenario is 16 688.26 KRW. Compared to the current market price of 9 310 KRW, Hana Pharm Co Ltd is Undervalued by 44%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
16 688.26
KRW
Undervaluation 44%
H
Multiples Across Competitors
Competitors Multiples
Hana Pharm Co Ltd Competitors
Hana Pharm Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| KR |
H
|
Hana Pharm Co Ltd
KRX:293480
|
161.1B KRW | 0.7 | 12.7 | 4.6 | 6.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879B USD | 13.5 | 42.6 | 28.7 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
576.7B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
256.6B CHF | 4.2 | 19.9 | 11.8 | 13.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.8B CHF | 5.4 | 21.6 | 13.3 | 17.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
222.9B GBP | 5.1 | 29.2 | 16.2 | 22.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.7B USD | 4.4 | 15.7 | 9.7 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.3B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.9B USD | 2.5 | 17.1 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
